Medtronic PLC $MDT Position Increased by Macquarie Group Ltd.

Posted by Francis Steltz on Jun 13th, 2026

Macquarie Group Ltd. grew its position in Medtronic PLC (NYSE:MDT – Free Report) by 7.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 441,967 shares of the medical technology company’s stock after buying an additional 30,791 shares during the quarter. Macquarie Group Ltd.’s holdings in Medtronic were worth $42,455,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in MDT. Lodestone Wealth Management LLC acquired a new stake in shares of Medtronic during the fourth quarter valued at approximately $27,000. Anfield Capital Management LLC raised its holdings in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares during the period. GoalVest Advisory LLC acquired a new stake in shares of Medtronic during the fourth quarter valued at approximately $29,000. Board of the Pension Protection Fund acquired a new stake in shares of Medtronic during the fourth quarter valued at approximately $29,000. Finally, Imprint Wealth LLC acquired a new stake in shares of Medtronic during the third quarter valued at approximately $31,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.26% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MDT shares. Wells Fargo & Company dropped their target price on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Deutsche Bank Aktiengesellschaft dropped their target price on Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a report on Thursday, June 4th. Evercore set a $106.00 target price on Medtronic and gave the company an “outperform” rating in a report on Thursday, April 9th. Rothschild & Co Redburn dropped their target price on Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Finally, The Goldman Sachs Group dropped their target price on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Seventeen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.00.

Check Out Our Latest Analysis on MDT

Medtronic Price Performance

Shares of MDT opened at $80.11 on Friday. The company has a market capitalization of $102.85 billion, a price-to-earnings ratio of 21.48, a P/E/G ratio of 2.30 and a beta of 0.58. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The business’s 50-day moving average is $80.85 and its 200-day moving average is $91.38.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The firm had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same quarter in the prior year, the company posted $1.62 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be issued a $0.72 dividend. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.6%. The ex-dividend date is Friday, June 26th. Medtronic’s dividend payout ratio is currently 76.14%.

Medtronic Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).